Premium
Latamoxef induced a severe coagulation disorder in older patients in China: Two case reports
Author(s) -
Zhu Yuanchao,
Shen Ji,
Wu Wenbin,
Sun Xuelin,
Hu Xin
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13266
Subject(s) - latamoxef , medicine , partial thromboplastin time , coagulopathy , prothrombin time , coagulation , coagulation disorder , moxalactam , gastroenterology , intensive care medicine , pediatrics , antibiotics , cephalosporin , biology , cefotaxime , microbiology and biotechnology
What is known and objective We present two cases of severe coagulation disorders induced by latamoxef, thereby revealing risk factors of coagulation disorder in latamoxef‐treated patients. Case summary Two very elderly patients developed haemorrhage, and coagulation tests showed a longer prothrombin time (PT), activated partial thromboplastin time (APTT) and a high international normalized ratio (INR). Latamoxef was thought to be responsible for the coagulopathy in these patients, and coagulation disorder was relieved after vitamin‐K intake. What is new and conclusion We report on two cases of coagulopathy in patients given latamoxef. Advanced age, deficiency in vitamin‐K intake, poor nutritional status, abnormal coagulation history, ongoing anti‐coagulation/anti‐aggregation therapy, renal dysfunction and polypharmacy are possible contributory factors, and should be looked out for when prescribing latamoxef.